(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 17.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Heron Therapeutics's revenue in 2024 is $127,044,000.On average, 2 Wall Street analysts forecast HRTX's revenue for 2024 to be $21,534,569,801, with the lowest HRTX revenue forecast at $20,745,344,730, and the highest HRTX revenue forecast at $22,323,794,873. On average, 2 Wall Street analysts forecast HRTX's revenue for 2025 to be $26,021,878,064, with the lowest HRTX revenue forecast at $25,736,253,752, and the highest HRTX revenue forecast at $26,307,502,375.
In 2026, HRTX is forecast to generate $31,223,247,105 in revenue, with the lowest revenue forecast at $31,223,247,105 and the highest revenue forecast at $31,223,247,105.